Good day and welcome to the Tenet Healthcare 4Q 2018 Earnings Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Brendan Strong, Vice President of Investor Relations. Please go ahead.

Good morning. Thanks, Amanda. The slides referred to in today's call are posted on the Company's website. Please note the cautionary statement on forward-looking information included in the slides. In addition, please note that certain statements made during our discussion today constitute forward-looking statements. These statements relate to future events including, but not limited to statements with respect to our business outlook and forecasts, our future earnings and financial position. These forward-looking statements represent management's current expectations, based on currently available information, as to the outcome and timing of future events but, by their nature, address matters that are uncertain. Actual results and plans could differ materially from those expressed in any forward-looking statement. For more information, please refer to the Risk Factors discussed in Tenet's most recent Form 10-K and subsequent SEC filings. Tenet assumes no obligation to update any forward-looking statements or other information that speak as of their respective dates, and you are cautioned not to put undue reliance on these forward-looking statements. I'll now turn the call over to Ron Rittenmeyer, Tenet's Executive Chairman and Chief Executive Officer. Ron?

Thanks, Brendan, and good morning. As we posted last evening in our release, Tenet delivered strong financial performance in 2018. Revenue, EBITDA and EPS were all above consensus. EBITDA was in the upper half of our outlook range, up 4.7% and up 9% on a normalized basis. We also more than doubled in EPs in 2018 to $1.86, which was above the high end of our outlook range. Each of our businesses rounded out 2018 with solid results. USPI delivered adjusted EBITDA less facility-level NCI growth of nearly 13%. After normalizing for the divestiture of Aspen. USPI’s case growth was 3.4%, including strong performance in both our surgical and non-surgical businesses. Conifer had a great year with adjusted EBITDA up nearly 35% on a normalized basis. They also improved margins by 330 basis points in the fourth quarter alone. Their performance throughout the year was a result of diligence in execution and a more pointed approach to cost management. Our hospitals delivered normalized EBITDA growth of 2%. Volume performance was below our expectations, but we do expect improvements throughout 2019 with our new leadership and new focus. And to that point, we are actually addressing gaps in performance with new leadership teams in specific hospitals and markets and with increased oversight and thoughtful direction from Saum Sutaria, our new Chief Operating Officer. One of the Saum's highest areas of focus in 2019 will be to lead the continued restructuring of our platform for organic growth in our hospitals. With that overview, I'd now like to take a few minutes and speak to some of the specifics from 2018. Clearly, it was a year of significant change, change in the way we think, change in the way we operate, change in the way we lead and engage our teams, and change…

Thanks, Ron, and good morning, everyone. We generated $684 million of adjusted EBITDA in the quarter, above the midpoint of our outlook range and up 7.4% year-over-year on a normalized basis. Adjusted EPS was $0.51, which was above the high end of our range for the quarter. Our Hospital segment generated $352 million of EBITDA, approximately $10 million ahead of our expectations for the quarter and up 0.3% after we normalize for the items listed on Slide 8. Ambulatory EBITDA was $245 million, which was 12.4% higher year-over-year and EBITDA less facility-level NCI was $151 million, up 7.1% after adjusting for Aspen which we divested in August. Conifer's EBITDA rose 10.1% to $87 million with margins up 330 basis points and adjusted free cash flow was $600 million in 2018. Turning to Hospital volumes, which are summarized on Slide 9. Adjusted admissions were flat excluding Chicago and planned service line closures in certain hospitals, which lowered adjusted admissions by 30 basis points and 50 basis points, respectively. We divested our last three Chicago hospitals in January. So these will no longer impact our same hospital metrics starting in the first quarter. Revenue per adjusted admission was very strong this quarter, up 5.4% after you adjust for California Provider Fee revenue and expense management was favorable again this quarter with cost per adjusted admission up 3.5% with excellent results in SW&B, Supplies and Corporate overhead, which we reduced by 28% in 2018. For the full year, our Hospital segment produced 2.4% EBITDA growth after you normalize for the items listed on Slide 8. Moving to our Ambulatory business on Slides 10 and 11. USPI continues to perform well. For the full year they produced case growth of 3.4%, EBITDA growth of 15% and EBITDA less facility-level NCI growth of 12.7%. This…

Thanks, Dan. I just want to close by saying we will enter 2019 with a renewed sense of urgency in volume growth, more effective execution and investing in our teams, while continuing to add external talent to our mix. We'll meet the headwinds and challenges openly and with a mindset geared to addressing each quickly and effectively. So, with that, Brendan, I think we are ready to turn it over for questions.

Great. Amanda, can you please start the queue.

[Operator Instructions] At this time, I'd like to take our first question from A.J. Rice with Credit Suisse. Please go ahead.

Thanks. Hello, everybody. First, maybe just quickly ask about the Hospital portfolio. You saw some improvement, particularly on pricing, obviously in the quarter. When you break down, I know you've got a lot of different markets performing in different ways. Would you highlight any markets that did particularly well, any that are particularly challenging? I know last time you talked about Detroit a little bit. Can you just give us some flavor for what's happening underneath the aggregate numbers in the Hospital portfolio?

Yes. Let me give a brief overview. Certainly, we were pleased with the Hospital results in the fourth quarter. As we mentioned in our prepared remarks, we came in about $10 million above where our expectations were at the outset of the quarter. So as you mentioned very strong revenue yield from acuity. We continue to focus on more complex service lines allocating capital to those type of service lines, as well as our negotiated contract rates. So certainly pricing was solid, costs continue to be well managed, across -- pretty much across the board. We certainly from a volume perspective, we're not where we want to be at this point, that's a key area focus of ours. We did call out a couple things in my script regarding Chicago, which we sold those hospitals, so that should be out of the numbers going forward. We did have some service line closures as well. We didn't call out Detroit this time, AJ. Detroit has not been an EBITDA problem and so we like our portfolio of hospital facilities and really looking forward to growing those markets and driving additional growth as we look into this year and beyond.

And then, just maybe my other question would be around just so flushing out one aspect of the guidance in USPI in the Ambulatory business. This year -- past year you had about, I think in the prepared remarks, you mentioned $240 million de novos and acquisitions, looks like in the guidance, you've got a little more moderation $150 million to $175 million, is that just sort of your typical starting point and you may do better or is there some reason to think it won't be as robust as it was last year? What does the pipeline look like, maybe some comments about that?

Pipeline looks really good. I would say, I would agree with you the $150 million to $175 million that is our starting point. We spend a little -- invested a little more than that in 2018 based on the attractive opportunities that were there and pipeline is very robust. So, I'll turn it over to Brett.

Thanks, Dan. Hey, A.J., it's Brett Brodnax. First of all, yes, we were very pleased with 2018 results from a development perspective as Ron mentioned. We invested $240 million for the year. We added seven new health system partners and we added 27 new facilities for the year. So it is one of the better years that we had as a Company from a development perspective. As we look at 2019, as Dan mentioned, our pipeline continues to be robust. We have guided $150 million to $175 million, but look if we continue to find high-quality acquisitions, it could be a little bit higher than that. And then, on the Hospital front, our health system pipeline continues to be very robust. We'll add as many health system partners in 2018 as we did -- I'm sorry in 2019 as we did in 2018, which will bode well for our future growth from both M&A and [audio gap].

Okay, great. Thanks a lot.

We'll take our next question from Ralph Giacobbe from Citi.

I certainly understand the sensitivity but just wanted to be clear on Conifer. Well, on the exclusivity with a partner, is that just a straight up sale or is it some sort of JV or other alternatives? I know you had mentioned other potential alternatives in the past. Just wanted to be clear on that.

Please standby. Brendan are you there?

We’re here. Did something happen? Did the line drop?

Yes. We can hear you now.

Okay. All right. So, please go ahead with the next question, Amanda.

I believe Ralph was still asking his question. Are you still there, Ralph?

Yes, I'm here. I'm here, thanks. I don't know if you got the question or not.

Yes. We didn't hear it at all. Sorry.

Okay. No worries. So, it was basically, certainly understand kind of the sensitivity, but I just want to be clear on Conifer, the exclusivity that you mentioned with a partner, is that a straight up sale or is it some sort of JV or other alternatives? I know you mentioned in the past potential alternatives, so just want to be clear on that.

Well, unfortunately, I can't answer that question. As I said to you, I'm really bound by very tight confidentiality agreement that we signed. That's why I tried to put that in my text, I appreciate your question and I understand why you want to know, but I -- this won't be that long of a process and I'm sure, we'll be able to answer that down the road, but right now, I'm really bound by this and all I can say is, it's one of the partners we've been speaking to and I can't get any -- that we've been looking at and I can't go any further than that what I said in the statement. I'm sorry.

Okay. No worries. Fair enough.

By the way, it is good news, so for the record. Go ahead.

Okay, fair enough, I will wait for that. So you had previously targeted 3% to 5% EBITDA growth for 2019. Maybe just help us on the drivers of what changed to give you a confidence to kind of raise it to that 4% to 7% range, maybe above and beyond, kind of the incremental cost saves that you -- that you saw. Thanks.

Sure. Good morning Ralph, it's Dan. Certainly, as we fine-tuned our outlook and modeling for this year, certainly one of the key factors of those -- cost efficiencies that we're going to execute on the new $200 million cost reduction initiative. So that's part of it. Certainly, as we examined each market with Saum coming on board in his role and diving deeper into each market looking at the opportunities there. And the trends we saw in the fourth quarter as well played a part in that as well. So, we increased a little bit. It was nice to see the hospitals perform better than we expected in the fourth quarter and looking forward to continuing to deliver those type of results on the hospital side.

Okay, thank you.

Our next question will come from Pito Chickering with Deutsche Bank.

Good morning, guys, thanks for taking my questions. On the USPI business, same-store revenues grew by 5% in 2018 and margin improved by 120 basis points, is that the right ratio going forward in terms of same-store revenue versus margin improvement? Or are we at a level where margin improvement becomes challenging and as because if I look at your same-store guidance for the ASC, is about 46% and back out about $10 million to $15 million of incremental EBITDA from acquisitions. I don't see a big margin improvement in your 10% to 12% guidance.

Well, obviously, as we, as we continue to grow the margin improvement is more of a challenge on the bigger base. We do have some facility-level margin improvement built into our guidance next year and I would say, we at a facility-level, not focusing on reported margins, we are still at 30% facility-level margins and we try to improve that a little bit each year.

Okay. Fair enough -- sorry.

Pito, it's Dan. Just the other thing I want to point out was that USPI has been performing incredibly well. We are very optimistic that that's going to continue. Organically just to remind you, we look at it as 2% to 3% case growth going forward, as well as 2% to 3% pricing growth and EBITDA growth -- EBITDA less NCI growth 8% to 10% on a long-term basis, we're going to do a little bit better than that this year, but -- and then when you think about the pipeline, we feel obviously, really good about the business.

Yes. I mean, it's been performing outstanding. I guess, actually on that same topic. Minority interest expenses guiding to grow I think double the rate of ASC EBITDA guidance, does that mean that some of the growth is coming from selling more shares to doctors or just something else is incurring in the minority interest line?

Yes, no, I was going to say, I think that's -- this is Brett. I think that's primarily driven by the fact that we did a couple of large acquisitions in 2018 that we acquired a minority position and it was a result of a health system partnership deal in one of our key markets around the country. So that's a large part of what's driving the higher equity in earnings.

Okay. And is there the possibility for buying back some of that MI in the next year or two?

We can -- we always continue to look for opportunities to buy ownership in existing facilities that we know well, obviously we don't have the due diligence risk related to buying ownership in facilities that we already own and operate, so we continue to look for opportunities within the portfolio to be there.

And Pito, just to remind you, during '18 we increased our ownership interest in USPI from 80% to 95% where we are very -- require purchased the remaining Welsh Carson interest.

Our next question from Ana Gupte with SVB Leerink. Please go ahead.

The question firstly was on the pricing growth where you saw, at least in the fourth quarter 5% plus ex the California Provider Fee you've successfully renegotiated contracts with Anthem, Cigna, and perhaps Humana. Can you talk about the sustainability of this, you're baking 2.5% to 3.5% I think into revenue per admission for '19 and how that plays out?

Ana, it's Dan. Well, certainly we were pleased to see the revenue yield in the fourth quarter of a little over 5%; for the full year, it was 3.6%. So again, that -- it is being driven by our focus in allocation of capital to higher acuity service lines and certainly our commercial book of business as well. So when we think about this year, obviously, you see the guidance here, assuming that it's going to be 2.5% to 3.5%, but we feel good about where we're at. From a contracting perspective, we're about 90% contracted for this year and little less than and half for 2020. So good visibility into pricing on the commercial side and we know where Medicare is going to be, Medicare about 2% growth year-over-year, so we feel good about pricing. And then cost management, obviously, we feel really strong about that in terms of what we've already executed on and what we think we can continue to execute on and capture additional cost efficiencies.

And then, on the USPI, just to follow up on the M&A landscape and the competitive dynamics there in terms of the availability of assets, surgeons, the multiples and what types of players are looking to buy here.

Yes. Hi, Ana. This is a Brett Brodnax again. So in terms of competition, the primary competition that we continue to see is related to other surgery center companies that are playing in the space. We're also seeing a little bit of a resurgence of competition from health systems around the country who are trying to figure out how they accelerate the ambulatory growth. Now, many of those health systems are looking to organizations like us to partner with, helping to do so. But there are health systems around the country who are deciding to go it alone and we deal those as obviously competitors. And I guess the third dynamic that we were seeing that would have been at this point it's large physician groups who are seeking private equity partners to consider a roll-up strategy. Now, some people would view that as competition; quite honestly, we see that as an opportunity, if we can work with some of these PE firms to help leverage our infrastructure as opposed to them having to replicate the infrastructure then. We think there is opportunity to partner with these PE firms to help them grow their footprint and scale out their business at a much more expeditious pace. In terms of the multiples -- I'm sorry, go ahead.

No, sorry.

Yes. In terms of the of the multiples -- go ahead.

Yes. Please go ahead. Sorry. No. I'm sorry about that. Go ahead.

Okay. In terms of the, in terms of the multiples, they're pretty -- they have been pretty consistent over the last year, year and a half; we're seeing multiples anywhere from 7 times to 8 times which has been pretty consistent with what we've seen in the recent past. We don't see that changing anytime soon and we think the market is pretty well stabilized. From a multiple perspective, I will say that the market is doing a better job in terms of discounting the risk associated with some of the assets around the country. But at the same time are paying a premium for the high-quality assets, but overall, the averages are pretty consistent.

We'll take our next question from Kevin Fischbeck with Bank of America. Please go ahead.

I just wanted to go back to the volume commentary since -- obviously appreciate all the things you're doing, operationally try and improve things, but just wanted to understand, the economy is doing pretty well, is there anything though that's like a counter act to 2019 where you're not going to see better volume growth this year? You mentioned of course, not EBITDA drag, but is Detroit still a drag or is there some other issue that's kind of holding you back this year that make it easier for us to have visibility into that improvement in 2020 and beyond?

Kevin, this is Saum. Thanks for the question. I'm pleased with the underlying foundation that we have in all of the remaining markets and we have opportunity across the market in our ability to improve patient access, scheduling, some of the things that Ron described in the beginning, that are just operationally going to allow us to serve those communities better and then obviously, we are focused on, but it takes time accelerating the pace at which we add high quality caregivers to our network. And then finally, if you think about the discussion that we've been having around the strengths of the USPI platform across the country, that applies very, very much to the markets in which Tenet has hospitals and so the integration with the Ambulatory platform across the different vehicles, ambulatory surgery, urgent care, imaging, all of those remain growth opportunities for us in the Tenet hospital markets which we will pursue over the coming year.

Okay. And then, just a question on the cost saves. Can you break out how much is coming from Conifer so just so that we know that if you end up do divesting Conifer, how much of that cost you still be thinking about as you look to the ongoing business versus the divested business?

Kevin, it's Dan. So on the bridge, you can see the walk from 2018 to 2019. We broke that down between the three business units that will realize this year. The full $200 million we'll provide more visibility in terms of these specific dollar amounts about business units little bit down the road, but in terms of, I would tell you that there are additional cost efficiencies opportunities at Conifer as well as all the other two business units and that's where we're going to be executing on, but at least for now refer to Slide 16, that at least gives you the thesis for 2019.

Okay. Thanks.

Okay. We'll take our next question from Josh Raskin with Nephron Research. Please go ahead.

We don't hear anything.

Actually, are you on the line?

We can't hear anything.

Yes. I'm here.

Go ahead.

Okay, awesome. Maybe just first on Conifer, I'm trying to reconcile two things that I presume are interrelated; first, the implied decline in the non-Tenet revenues seems a little steep this year, and I'm just wondering of the hospital divestitures, how many terminated the contracts with Conifer? And then second, looking at the $40 million headwind from the divestitures in the bridge, it seems to suggest maybe $160 million of lost Conifer revenue if we assume maybe a 25% margin or maybe $4.5 billion of managed revenue. So, I'm just trying to reconcile this. It just seems to imply a larger number than I would have expected.

Hey, Whitt. [Ph] It's Dan. The $40 million or the $30 million number that you've seen on Slide 16, I think that's what you're referring to. Yes. There was obviously few pieces in there and let me try to hit a few of them and then I'll turn it over to Steve in terms of broader overview. But, the $30 million of growth, some of that is attributable to contracts we have with customers where we have price escalators in there or rate escalators that will certainly we anticipate drop straight to the bottom line. So certain contracts we have to be the escalators to be based on CPI or another metric. So, that's fair size of amount in that line. Certainly as Tenet grows its business there's additional revenue that Conifer realizes and we don't believe we would need to add any additional resources either, so there's a little bit of that in there. And then the mix of business, it's important as we think about the types of services we're providing to all customers certain point solutions, depending on the mix of those point solutions, the margins can be much more attractive. We've also and in certain cases decided to exit some business that wasn't necessarily the most attractive and may have had smaller margins or maybe actually slightly dilutive margins. So, a whole list of items that go into that in terms of what drives that $30 million. Steve, do you want to address the broader…

Yes. Dan, I think, the comment you made on slide 15, you mentioned $150 million in revenue decline, as we move it from say was a Tenet hospital and it gets divested and then moves into commercial. I mean, what happens is, we typically have a two-year transition service agreement as a result of that, and so those accounts now are starting to as you come off the portfolio, lot of cases as you know they were required by some organizations had internal operations, you know something happened obviously as last year and that's happening again in 2019. So it's kind of part of the process, as we continue to go. So and Dan mentioned, something is result of that and another part is result of contracts, we just did not feel we want to continue with as they're coming up for renewal, they're profitability in our things like that. So it's a kind of where it's at.

So of the four just to be clear, the $40 million headwind, how much of that is coming exclusively from divestitures. How much is coming exclusively from may be terminated contracts or how much is coming from business that you intentionally walked away from and presumably it wouldn't be much of an EBITDA tailwind if it was financially attractive?

The vast majority of that number is coming from the divestitures.

Okay, perfect. And one last once, since I heard Jason earlier. Looking at the $45 million of acquired EBITDA in the Ambulatory division this year, can you break out how much of that is expected to flow through unconsolidated versus the consolidated? And I guess the corollary there is that the equity earnings growth and implied margin improvement looks really high this year. So I'm just trying to flush out where all that growth is coming from. Thanks.

Hey Whitt, [ph] it's Jason. How are you?

Good.

Good. I can't tell you how much of our unidentified M&A is going to be unconsolidated versus consolidated. We go after the deals that they present themselves and we've never been effectively able to guide to that. I will say, to your point on equity and earnings, the vast majority of that is what Brett mentioned earlier that we had a couple large acquisitions right at the end of the year that really don't impact '18 but are coming through the equity line in '19.

We'll take our next question from Josh Raskin with Nephron Research. Please go ahead.

It's Mary on for Josh. My question is just round ASC seasonality, which didn't seem strong this year in the fourth quarter, is there anything to call out on the volumes there?

Hi, Mary. Yes, this is Ron. First of all, if you look at the full year, we are pretty pleased with the overall volume growth of 3.4%. Now, if you look at Q4 specifically, you have to take into consideration that the Q4 in 2017 was at 4.6%. So we had a pretty significant comp that we dealing with and that's really the primary driver of results in Q4 of 2018.

And then just on the inpatient surgeries, this quarter were a little bit weaker than we were expecting, is this primarily delayed due to Detroit or the service line closures?

This is Dan. Certainly, when we think about the surgical volumes, we need to grow those, we are not necessarily pleased where our aggregate numbers are, but I would tell you that's obviously one of the areas when we think about allocation of capital and focusing on higher acuity service lines, that the strategy is to grow incremental surgical line, whether it's in the inpatient settings or outpatient setting.

Our next question will come from John Ransom with Raymond James.

Last year you had some losses in the California capitation business that you called out in the third quarter, what's the comparison in your '19 guide versus what you experienced in '18?

Hi, John, it's Dan. 2019, the risk contracting business in Southern California, you should think about it in terms of roughly $15 million for the full year, probably a little more weighted into the first half. We've changed our management, we're getting our arms around the business and we'll get it solved and -- but it going to take a little bit more time.

Okay. And then secondly, just going back to the Conifer business, not Conifer itself, but what is this market for revenue cycle hospitals, is it's still growing or we hit a maturity point in your opinion?

I'll take that John, this is Steve. No, I don't think we hit maturity point. I mean, as we're looking over the years, clearly have estimates on how we think markets are going to grow. I think, in some cases, it hasn't grown as fast as we thought early on. We were seeing a lot happening with all these EMRs going into hospitals, lot of focus on that for several years. They're kind of coming out of that now whether it's conversions to Epic or Cerner. They are now starting to focus on bottomline, bottomline improvement, having reducing the overall cost structure average [indiscernible]. We're clearly one of those solutions across the portfolio. There is lots of conversations happening in the market. I think, we're seeing more we call performance solutions or point solutions, areas around [indiscernible] management, eligibility services, self-pay, it's work around your coating, your clinical documentation work, a lot more uptake in that area right now. In the full outsourcing are very strategic moves so there has been think few of those in the market in general. I don't think you're going to see still tons of those going forward. But, you are seeing a lot of solution areas, a lot of these areas of specialty but everybody is moving toward outsourcing. A lot of outsourcing is done today, but typically looking for partner that can aggregate across portfolio and that's we think Conifer really differentiates ourselves, coming to marketplace, coming in with a complete suite of solutions for the market. Now, as you bring in technology enhancements whether it's around AI, RPA, touch process languaging [indiscernible] everybody is looking at calling today these one-offs. We have to break that into our entire suite to market.

And last one for me. Dan, if we just look at M&A contribution and adjust for timing and let's assume you hit the midpoint of your guidance. What's the 2019 EBITDA lift from M&A and this will include stuff that you bought in '18 that you announced for the full year, plus what you plan on buying in '19. Can you kind of give us the total EBITDA lift year-over-year.

Yes. I would -- John, on Slide 16, we call that out. And it's $45 million; that's a combination of deals that were done in 2018, as well as some deals that were done that we anticipate will be executed on -- in 2019. You may ask question or what's the breakdown between prior year deals, what we anticipate related to investments, we'll make this year. It's probably roughly one-third of that $45 million would relate to investing to make in 2019, and the remaining related to prior year deals.

Yes. That's what I was getting at. All right. Thanks so much.

Our next question will come from Brian Tanquilut with Jefferies.

Ron, so, you guys have done a really good job with the $250 million in cost cut. So, as we think about the next 200, do you mind just walking us through some specifics and where do you think you can squeeze more and how much harder with the extra 200 it’d be to achieve?

Well, I think the 200 -- the problem with cost cuts, it's always hard to achieve. But the reality is that we, I think we have a fairly good sense that there will be more as we do further integration. We are going to consolidate, for example, our office structure here in Dallas into one building, that may sound tight, but it actually will force a lot more integration quicker and we do need to do that. In the field Conifer is going to continue to look at locations and could do consolidations. In the hospitals, we're doing the same type of thing. We're always going through jobs and premium labor and contracting labor and why do we need that and should these be permanent jobs at a lower rate than UK for a premium contracted labor. So there's a lot of effort on a lot of fronts. There's no silver bullet to this. We've talked about offshoring which across the country, there will be -- that activity will begin to take shape this year and move at a reasonable pace. So to me, there's a lot of, there's people stuff, there's processed stuff. Paola Arbour, our IT person is sitting here, he is spending a lot of time, looking at upgrading systems and investing by eliminating some inefficient stuff and some things that have aged out to doing some new things, which will be an investment that we can almost cover just by the fact that the money, we'll save by the changes we'll make. So all of those things add up to I think a reasonable line of sight to the $200 million, but I would be kidding if I said I have it took totally defined down to the number, because we're not, we're not that good but throughout the year like we said last year as we kept increasing that there are places that we know we haven't finished yet in every one of the divisions, and in every part of the effort we've made to integrate. So kind of a long way to say that it's a broad program, but within that program it's very specific. So we are, we are doing it and we are very active in it and I would say it's engaged with my whole team and I think last year was a interesting year, in that people had to think about doing it, it wasn't something that was kind of normal. I think this year, we're already in the game and we understand it and I think the ability to address it is much more, much more ingrained in the organization than it was a year ago. So we'll see where it goes but that is my intent. I'm comfortable with the number. I'm probably the only guy in this room that's comfortable with the number, but I believe the number is realistic and we should be able to achieve it. So, I hope that answers.

I appreciate that and then my follow-up for Dan, as we think about leverage. I mean, you talked about 5 times. And I think in the past you've mentioned a target of getting to 5 times leverage by end of '19, is that still the goal and then how do you bridge that given the guidance ranges that you provided for the year? Thank you.

Hi, Brian, it's Dan. Certainly, we remain committed to getting to 5 times or lower from a leverage perspective. Listen, you can do the math based on the guidance we have, we still have a little more work to do to get there and that's what we're focused on. Every time we make an investment decision, we are always thinking about the implications on our leverage. So I can assure you that. So all I say is we absolutely remain committed to getting to 5 times or lower.

This Ron, and I totally underscore that from the enterprise standpoint. And we continue to look at assets and evaluate assets relative to their fit and where that's going, we're not going to talk about anything specific. As I've said before we'll never pre-announce, but I mean, those things are ongoing and a very active part of our process, we're not married to anything and -- so anyway.

And we'll take our last question from Sarah James with Piper Jaffray.

Thank you. There's been an influx of investment in urgent care from many sources. How do you think about the risk of market over saturation and maintaining share during this influx?

Sarah, this is Saum, thanks for the question. I agree with you that there's been an influx of investment broadly speaking in the urgent care space though the models are often it's not the same in certain different population in that market. Remember in many markets, including some of ours there's shortages in primary care as well that are being fulfilled from a demand perspective by urgent care centers as they develop and then of course, you have the retail clinics within big box retail that serve perhaps a different purpose in different population. I think one of the things that you're seeing is that urgent care centers are increasingly providing slightly higher acuity care as well and taking on patients that may have some more chronic illness as well. So when I add that up at this point, it's not surprising to me that we're seeing more investments come in, they're different models, they're not all the same. And it's not entirely obvious which models will sustain over the long term, but I don't see yet a major problem of over saturation across the country.

Thanks. And follow-up here. What you guys are doing on marketing and sales strategy is really innovative. I'm wondering if you're seeing it move the needle yet on volume or if it's having any impact on your strategy of what specialties and what mix you want to have.

I don't know if it's that finite. I would tell you that it's clearly moving the needle on energizing our people in the field and energizing our teams around the country. They walk into a hospital, they can see their picture on the advertisements in the lobby and they see their stuff on bus wraps as they go by me, it's an energizing experience to feel your part of the community and you are making a difference. I believe and we believe from at least initial reads that it's having a very positive impact and I think over this is -- marketing is an effort, it takes time and it's how do you build a foundation in community and that's what we're doing. So we feel good about it. We think that the initial response at least the visual initial responses are supportive. The real question will be how the numbers tumble and how the service lines fallout. But we're a little early for that, considering we just really kicked this off toward the end of last year or so. And I think that's it. Brendan?

Thank you. At this time, I'd like to turn the call back over to our presenters for any additional or closing remarks.

Great. Thanks a lot Amanda. We thank everyone for joining us today. Our next event will be the Barclays Global Healthcare Conference on March 12th, so we look to meeting you there and if you have any additional follow-up questions you can reach me at 469-893-6992. Thanks.

This concludes today's call. Thank for your participation. You may now disconnect.